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Background: The main anchoring proteins of myocardial cells with each other and with the extracellular matrix are integrins present in the
membranes of myocardial cells. These integrins are important for maintaining the architecture of the myocardial tissue and the
mechanotransduction in the heart. Heart failure leads to various alterations in the myocardium, such as changes in morphology, and in
expression ofmRNAs,miRNAs, and proteins. Left ventricular assist device (LVAD) support in heart failure patients has been described to induce
reverse remodeling of themyocardium and thus to (some degree of) reversal of the aforementioned alterations. In this study, we evaluatedwhether
changes in expression of integrins α-1, -3, -5, -6, -7, -10, -11 and β-1, -3, -5 and -6 play a role during reverse remodeling.Methods: Three-step
immunoperoxidase staining procedures were applied on frozen heart tissue sections to locate the various integrins tested. Integrin mRNA
expression was established by standard Q-PCR procedures. Results: It was shown that mRNA expression of several integrins changes
significantly during LVAD support, however without subsequent changes in immunohistochemical detectable quantities. Various integrins
showed different locationswithin themyocardium.Conclusion: LVAD-induced reversed remodeling did not result in significant integrin protein
expression, although changes in integrin mRNA expression suggested an adaptation to unloading.© 2012 Elsevier Inc.
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Open access under the Elsevier OA license.1. Introduction
Trans membrane receptors such as integrins are important
for the dynamic interaction between intracellular processes
and the extracellular environment [1,2]. Integrins are
expressed in all cellular compartments of the myocardium.
They are critical to its form and function and are essential in
regulating cellular processes [1–3]. Anchoring cardiomyo-None of the authors has anything to disclose.
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Open access under the Elsevier OA license.cytes to the extracellular matrix (ECM) is mainly mediated
by integrins and in this respect very important for
maintaining the proper architecture of the total myocardium
and for the mechanotransduction [4]. Structural remodeling
during the development of heart failure is characterized by
rearrangement of the architecture of the cardiac ventricular
wall. It involves among others hypertrophy of the myocytes,
fibroblast proliferation, increased deposition of ECM pro-
teins, and altered expression of miRNAs [5–7].
Left ventricular assist devices (LVAD) are mostly used as
bridge to heart transplantation (HTx) in patients suffering
from end-stage heart failure and induces partial recovery of
ventricular functions [8], improved condition of the patients
[9], reduction in cardiomyocyte size [10], changes in
contractile fibers [11,12], and depending on the type of
heart failure [ischemic heart disease (IHD) or dilated
cardiomyopathy (DCM)], to partial recovery of miRNA
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of ECM and basal membrane components have been
described [13].
As both cardiomyocyte size and ECM volume changes
during LVAD support, we wondered how integrins as
anchoring proteins between both alter during this support.
The goal of this study was to analyze the changes in mRNA
expression by quantitative PCR of several integrins (α1, -3,
-5, -6, 7,- 10, -11 and β-1, -3, -5 and -6) in the myocardium
of heart failure patients before and after LVAD support. To
establish the location of integrin-α5, -α6, -α7, -β1 and β6,
immunohistochemical techniques have been used. Previous-
ly, we showed that collagen IV expression diminished in the
basal membrane after LVAD support. This is in contrast to
laminin that did not alter [13]. To explore the role of the basal
membrane further, also the changes in perlecan expression
were studied. Perlecan is an important heperan sulfate
proteoglycan in the basal membrane; its functions in
anchoring matrix proteins and its expression change with
mechanical stretch [14].2. Methods
2.1. Patients and tissue samples
Sixteen patients (age: 38±12 years; 14 men and 2 women)
with refractory end-stage heart failure diagnosed with IHD
(n=7) or with DCM (n=9) were selected for this study (Table
1). Because of the different etiologies of DCM and IHD, both
groups were analyzed separately. All patients were treated
with a pneumatic LVAD (Heart-Mate I, Thoratec, Pleasan-
ton, CA, USA) as a bridge to HTx, between 2000 and 2005.
At the time of LVAD implantation, all patients were in
NYHA functional class IV, and in NYHA functional class I
while on LVAD support. Prior to LVAD implantation, all
patients received intravenous inotropics because of hemo-Table 1
Patient characteristics
No. Age Diagnosis Gender
1 56 IHD Male
2 57 IHD Male
3 45 IHD Male
4 57 IHD Male
5 36 IHD Male
6 26 IHD Male
7 39 IHD Male
8 34 DCM Female
9 17 DCM Male
10 47 DCM Male
11 35 DCM Male
12 32 DCM Female
13 25 DCM Male
14 32 DCM Male
15 25 DCM Male
16 46 DCM Male
DCM: dilated cardiomyopathy, IHD: ischemic heart disease, LVAD: left ventricudynamic deterioration. Cardiac medication was discontinued
initially in all patients after LVAD implantation (except for
aspirin), but resumed if necessary (Table 1). Informed
consent to participate in this study was obtained from all
patients before LVAD implantation. The pre-LVAD biopsy
(LV apical core) was obtained at the time of LVAD
implantation. These biopsies were compared with LV tissue
specimens of the explanted heart after HTx (post-LVAD),
taken from the apical half of the LV. All biopsies were
directly frozen. Normal myocardial tissue was obtained from
vital organ donors from which the heart could not be used
because of noncardiac reasons (n=2) and from autopsy on
patients with no pathology of the heart (n=3). These biopsies
served as a control.
2.2. Immunohistochemistry
For the immunohistochemistry (IHC) of integrins, only
(monoclonal) antibodies were selected that showed a strong
staining without aspecific background on myocardial
tissues. Therefore, only a limited number of integrins
could be tested by IHC. Three-step immunoperoxidase
staining to detect the localization of various integrins (and
perlecan) was performed on sections prepared from frozen
heart tissue samples obtained pre- and post-LVAD. Eight-
micrometer-thick sections were mounted on silan-coated
glass slides. Frozen sections were air dried at room
temperature, fixed in acetone (10 min), washed in
PBS/Tween-20 for 10 min, and incubated with the primary
antibodies ( goat anti-integrin α-5; -anti-integrin α-6, and
-anti-integrin α-7, mouse anti-integrin β-1D or rabbit anti-
integrin β-6; Table 2) for 1 h at room temperature.
Next, sections were washed in PBS/Tween-20 (10 min)
and fixed in formalin (4%) to cross link the antibody to the
tissue. Endogenous peroxidase was blocked by incubation in
a blocking buffer (20 min) followed by washing in
PBS/Tween-20 (30 min), and the sections were incubatedDays on LVAD Medication during LVAD support
138 None
225 None
259 2.5 mg Ramipril
263 None
325 2×4 mg Perindopril
357 None
548 3×6.25 mg Capoten




219 3 mg Captopril
263 1×25 mg Losartan
286 4 mg Perindopril
330 2×10 mg Fosinopril
484 3×50 mg Capoten
lar assist device.
Table 2
Overview of antibodies used for immunohistochemistry
Primary antibody against Obtained from Dilution Secondary antibody/dilution: 1/250 Tertiary antibody
Integrin-α5 Tebu, Heerhugowaard, The Netherlands 1/50 Rb-anti-Go PO Rabbit- Powervision
Integrin-α6 Bioconnect, Frankfurt am Main, Germany 1/250 Rb-anti-Go PO Rabbit- Powervision
Integrin-α7 Tebu, Heerhugowaard, The Netherlands 1/250 Rb-anti-Go PO Rabbit- Powervision
Integrin-β1D Abcam, Cambridge, United Kingdom 1/20 Rb-anti-Mo PO Rabbit- Powervision
Integrin-β6 Santa Cruz Antibody, Heidelberg, Germany 1/10 Rb-anti-Ra PO Rabbit- Powervision
Perlecan Bioconnect, Frankfurt am Main, Germany 1/250 Rb-anti0Mo PO Rabbit- Powervision
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at room temperature. All secondary antibodies had been
absorbed before use with 10% normal human serum to avoid
cross reaction to human IgG. After another washing step in
PBS/Tween-20 (30 min), the sections were incubated with
Rabbit HRP Powervision (Immunologic, KliniPath, The
Netherlands) for 30 min at room temperature. Finally, the
slides were washed again in PBS/Tween-20 for 30 min and
incubated in a 3.3.di-aminobenzidineterachloric acid (DAB)
solution for 10 min (room temperature), washed with aqua
dest (10 min), and counterstained with Mayer's hematoxylin.
Slides were dehydrated and mounted in Pertex.
The intensity of the IHC staining was scored (in a
blinded fashion by two observers using a grid created with
Image J software for Windows) on a semiquantitative scale
ranging from negative (score=0), till intermittent/mild
staining (score=1), moderate/diffuse staining (score=3),
and strong/continuous staining (score=5). At least 5
adjacent high-power microscopic fields (magnification×40)
per tissue section were scored. Per patient, at least 6 sections
were studied. In case of IHD, only vital cardiomyocytes
were examined. Necrotic or fibrotic areas were excluded
from examination.
2.3. Quantitative PCR
The mRNA was isolated from 20 frozen tissue sections
(thickness 10 μm) of myocardial biopsies using Dynabeads
Oligo(dT)25 (Invitrogen Dynal AS, Oslo, Norway). cDNA
synthesis was performed using oligo-dT, random primers,
and superscript-III. The primer/probe combinations used for
Q-PCR were from Applied Biosystems (Foster City, CA,
USA) either in a low-density array (LDA) or as single tests
(Taqman Gene Expression Assays: TGEA). The LDAs were
used according the manufacturer's instructions and for
TGEAs per reaction 12.5 μl Taqman universal master mix
(Applied Biosystems), 1.25 μl primer/probe, 6.25 μl milliQ
was used and 5 μl cDNA sample was added. The Q-PCR
reactions were carried out by the 7900 sequence detection
system of Applied Biosystems. Thermal cycling comprised a
denaturation step at 95°C for 10 min followed by 45 cycles
of 95°C for 15 s and 60°C for 60 s. All experiments were
performed in duplicate. For standardization, the expression
of three endogenous control genes was tested in parallel.
These three genes showed differences in expression level but
the relative expression remained the same. The meanquantification cycle threshold (Cq) value of all samples
was 29.31±0.91 for HMBS, 19.35±1.05 for GAPDH, and
25.06±1.24 for PGK-1. We decided to use GAPDH for
quantification as its expression level lies within the most
reliable Ct range. To quantify the data, the comparative Cq
method was used, resulting in relative mRNA quantities
(RQ) [15].
2.4. Statistical analysis
The Q-PCR data were analyzed using the paired and
unpaired t-test when appropriate (based on normal distribu-
tion tested by the Kolmogorov–Smirnov test). All data were
calculated with the statistical package of Prism 4.0 for
Windows. A P value b.05 was considered statistically
significant. The fold change between pre- and post-LVAD
gene expression for the differentially expressed genes was
determined by calculating the RQ post/RQ pre ratio for each
patient. Furthermore, the average ratio of all patients was
determined. Fold change was Log2 (average ratio).3. Results
3.1. Immunohistochemistry of integrins
To evaluate the location and expression of the different
integrins in the cardiovascular system pre and post LVAD
support, frozen tissue sections were stained by a conven-
tional three-step immunoperoxidase staining and scored.
The location of integrin-α5, -α6, -α7, -β1, and -β6 was
established. The results, as summarized in Table 3 and Fig.
1, show that integrin-α6 is restricted to the capillaries and
integrin-β1 to the membrane of cardiomyocytes. Integ-
rin-α7 occurs in the cardiomyocyte membrane, the
intercalated discs, and in the cytoplasm of the cardiomyo-
cytes. Integrin-β6 was expressed in vascular smooth muscle
cells and intercalated discs, and integrin-α5 was detected in
the cytoplasm of cardiomyocytes, in stromal tissue, as well
as in the “larger” blood vessels (latter two not shown as
IHC staining).
There were no statistically significant differences in the
degree of positive staining of the various integrins examined
in the cardiovascular system before and after LVAD support.
The results obtained were similar in tissues obtained from
IHD patients and from DCM patients.
Table 3
Location of integrins ⁎ in cardiovascular system
Integrin Cardiomyocyte membrane Intercalated discs Cardiomyocyte cytoplasm Capillaries Stromal tissue Larger vessels
α5 Negative Negative Positive Negative Positive Positive
α6 Negative Negative Negative Positive Negative Negative
α7 Positive Positive Positive Negative Negative Negative
β1 Positive Negative Negative Negative Negative Negative
β6 Negative Positive Negative Negative Negative Positive
⁎ Integrins were detected by three-step immunoperoxidase staining.
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cardiomyocytes (Fig. 2). In both patient groups, the
expression in the pre-LVAD situation was significantly
less than in the controls. Only in IHD patients LVAD support
resulted in some increase; however, the expression remained
below control levels.
3.2. mRNA expression of integrins
Messenger RNA expression of integrin-α1, -α3, -α5,
-α6, -α7, -α10, -α11, -β1, -β3, -β5, and -β6 were tested by
Q-PCR. Statistically significant changes in mRNA expres-
sion due to LVAD support were only observed in 5 out of
11 integrins tested (Fig. 3) in either one or both patient
groups. However, these 5 integrins did not show significant
differences with the healthy controls (both pre- and post-
LVAD) except for integrin-α6 in DCM patients. In this
case the pre-LVAD level is significantly lower than control
level (Fig. 3).
Expression of integrin-α1, -α6 and -α10 mRNA
significantly increased after LVAD support in DCM patients
compared to pre-LVAD. The observed increase was 0.98-
fold (P=.014), 1.40-fold, (P=.007), and 2.47-fold (P=.023),
respectively.
In IHD patients significant increases in mRNA expression
were seen after LVAD support for integrin-α6 and -β6; 23-
fold (P=.046) and 9.34-fold (P=.026), respectively, whereas
a decrease (0.41-fold, P=.039) was measured for
integrin-α5.4. Discussion
Integrins mediate interactions between cells, basal
membrane and the extracellular matrix (ECM) that are
essential for several cellular processes. Intact integrin
function has been related to anti-apoptotic signaling and
cell survival [16], induction of post-infarct cell migration
and myocardial repair [17], activation and regeneration
involving epithelial–mesenchymal transition [18], as well as
to a normal progression of cardiomyocytes through the cell
cycle [19].
Structural remodeling of the ventricular wall in patients
with heart failure involves changes in the ECM [5,6,20],
cardiomyocytes, and basal membranes [13]. The changes
observed in the patient group of this study were the same asdescribed by Bruggink et al. [13,20]. Since integrins form the
contact between cells and their surrounding matrix and are
important in the mechanotransduction of the contracting
cardiomyocytes, it might be expected that if changes in the
ECM occur this will be reflected in integrin expression in the
myocardium. Furthermore, it has been described that LVAD
support in heart failure patients leads to at least partial
normalization of the heart condition [8,9] among others
reflected in changes in regulatory miRNA expression [7].
In this study, it was shown that LVAD support also
induces significant differences in the mRNA expression of
integrins. The alterations observed were different in DCM
and IHD patients (Fig. 3). In DCM patients LVAD support
caused a significant increase in the mRNA expression of
integrin-α1, and -α10. However, in IHD patients a
significant decrease in the expression of integrin-α5 and an
increase in the expression of integrin-β6 was observed. This
is interesting as integrin-α5 is the only known ligand of
integrin-β6, but the mRNA expression of both follow a
different pattern. The only similarity between the two patient
groups was the increase in the expression of integrin-α6
mRNA. Similar changes in integrin expression have been
described by others, such as Hall et al. [21] and Schipper
et al. [22] using gene profiling.
Despite the differences observed in the mRNA expres-
sion, we did not detect large differences in quantities of
integrin protein expression by IHC [23]. Whether this is due
to a high turnover of the integrin proteins, post-transcrip-
tional regulation, or a consequence of integrin shedding [3]
needs further study. Another explanation may the difficult
accessibility of integrins for the antibodies used, which
prevents detection of subtle changes during LVAD support
in amount and expression of integrins. We did however
detect differences by the IHC analyses in the location of the
integrins studied (Table 3).
Integrin-β6 mRNA was strongly up-regulated after
unloading in IHD patients (Fig. 1). This integrin is known
to be up-regulated during tissue remodeling and wound
healing [20], and similar processes may be involved in
reverse remodeling. It is likewise remarkable that the only
integrin mRNA expression that was increased after LVAD
support in both patients groups (integrin-α6) was located
especially in the wall of capillaries in the myocardium and
not in the cardiomyocytes. It has been described that
integrin-α6 is important for regeneration and repair process-
es [17,18,22] and so it might stimulate the regeneration
Fig. 1. Immunohistochemical staining of myocardial tissue pre- (A, C, and E) and post (B, D, and F) LVAD support. Integrin alpha-6 (A, B) was mainly found in
the smaller capillaries; integrin alpha-7 showed intermittent membrane staining (score 1; C) or continuous membrane staining (score 3; D); integrin beta-1
showed continuous diffuse membrane staining (score 3; E) and continuous non-diffuse membrane staining (score 3; F).
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capillaries (resulting in a better blood supply) during the
remodeling of the myocardium. This thesis is supported bythe fact that the presence of integrin-α6 attracts mesenchy-
mal stem cells [24] that might help to accomplish repair
processes in the affected myocardium.
Fig. 2. Immunohistochemical detection of Perlecan protein. Perlecan was
found to be widely expressed on the membrane of cardiomyocytes; in
control tissue (C) as well as in cardiomyocytes from HF patients pre- (A) and
post-LVAD (B) support.
Fig. 3. Significant mRNA changes during LVAD support of different
integrins in DCM or patients suffering from dilated cardiomyopathy
[ischemic heart disease (IHD)].
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the basal membrane did alter strongly immunohistochemi-
cally. That change was not paralleled by changes in laminin
content [13]. In this paper we showed that perlecan (anotherimportant component of the basal membrane) did not show
any significant change in protein expression during LVAD
support and was pre- and post-LVAD similar to control
expression. So, the previously shown changes during LVAD
support in the basal membrane seem to be confined to the
collagen IV content, and although perlecan is affected by
mechanical stretching [14], LVAD unloading seems not to
alter its expression. Our data indicate that integrin mRNA
expression alters during LVAD support, as was expected in
view of the morphological changes that occur, and based on
data published previously [21,22,25]. Especially the expres-
sion of integrin-α6 seems to be an interesting hallmark in
these changes. However, the detected changes (mostly an up-
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protein level and location, as detected by an IHC approach.
This indicates that either the protein regulation is more
complex than just based on mRNA expression or the
histochemical approach was not able to detect the subtle
integrin changes induced by LVAD support, or both.
In summary, despite previous reports on changes in
integrin expression after LVAD support, suggesting a role as
anchoring proteins in reverse remodeling, the changes
observed in the present study on integrin expression and
basal membrane protein expression showed no or in most
cases only marginal changes. However, this does not exclude
a role for these molecules in remodeling as such.5. Study limitations
The set of tissues pre- and post-LVAD tissues analyzed in
this study is unique in its composition and availability.
However, the group of LVAD patients studied was relatively
small and this makes statistical analysis on the influence of
medication, age, and gender difficult. No significant
differences were observed in patients (both DCM and
IHD) that received additional treatment or not. Also, the
duration of support varied (55–548 days), which might have
influenced the data. However, the changes in expression of
integrins (if observed at all) did not show any significant
correlation with time of support (data not shown).
A final limitation is the availability of control heart tissue.
We used myocardial tissues from autopsy hearts from
patients without cardiac problems and non-used donor
hearts. No differences were observed in integrin expression
between both controls in this study. The pre- and post-
LVAD myocardial tissues were directly fixed or frozen after
operation and were therefore relatively fresh. Still, we cannot
totally exclude that this has influenced the comparison
between LVAD tissues and controls.
Acknowledgments
Dr. M.F.M. Van Oosterhout was supported by the
Nederlandse Hartstichting (Dutch Heart Foundation); project
number 2004T31.
References
[1] Ross RS, Borg TK. Integrins and the myocardium. Circ Res 2001;88:
1112–9.
[2] Giancotti FG, Ruoslathi E. Integrin signalling. Science 1999;285:
1028–32.
[3] Goldsmith EC, Carver W, McFadden A, Goldsmith JG, Price RL,
Sussman M, et al. Integrin shedding as a mechanism of cellular
adaptation during cardiac growth. Am J Physiol Heart Circ Physiol
2003;284:H2227–34.
[4] Nawata J, Ohno I, Isoyama S, Susuki J, Miura S, Ikeda J, et al.
Differential expression of alpha 1, alpha 3 and alpha 5 integrin subunits
in acute and chronic stages of myocardial infarction in rats. Cardiovasc
Res 1999;43(2):371–81.[5] Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RL,
et al. B-type natriuretic peptide exerts broad functional opposition to
transforming growth factor-beta in primary human cardiac fibroblasts:
fibrosis, myofibroblast conversion, proliferation and inflammation.
Circ Res 2004;94:453–61.
[6] Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T,
Levick SP, et al. The relationship between myocardial extracellular
matrix remodelling and ventricular function. Eur J Cardiothorac Surg
2006;30:604–10.
[7] Schipper MEI, van Kuik J, de Jonge N, Dullens HFJ, De Weger RA.
Changes in regulatory microRNA expression in myocardium of heart
failure patients on left ventricular assist device support. J Heart Lung
Transplant 2008;27:1282–5.
[8] Latif N, Yacoub MH, George R, Barton PJ, Birks EJ. Changes in
sarcomeric and non- sarcomeric cytoskeletal proteins and focal
adhesion molecules during clinical myocardial recovery after left
ventricular assist device support. J Heart Lung Transplant 2007;26:
230–5.
[9] de Jonge N, Kirkels H, Laphor JR, Klöpping C, Hulzebos EJ, de la
Riviere AB, et al. Exercise performance in patients with end-stage
heart failure after implantation of a left ventricular assist device and
after heart transplantation: an outlook for permanent assisting? J Am
Coll Cardiol 2001;37:1794–9.
[10] Schnee PM, Bergheim M, Poindexter BJ, Buja LM, Gummato C,
Radovancevic B, et al. Location and density of alpha- and beta-
renoreceptor sub-types in myocardium after mechanical left ventricular
unloading. J Heart Lung Transplant 2008;27:710–7.
[11] de Jonge N, van Wichen DF, van Kuik J, Kirkels H, Lahpor JR,
Gmelig-Meyling FH, et al. Cardiomyocyte death in patients with end-
stage heart failure before and after support with a left ventricular assist
device: low incidence of apoptosis despite ubiquitous mediators. J
Heart Transplant 2003;22:1028–36.
[12] de Jonge N, van Wichen DF, Schipper ME, Lahpor JR, Gmelig-
Meyling FH, Robles de Medina EO, et al. Left ventricular assist device
in end-stage heart failure: persistence of structural myocyte damage
after unloading. An immunohistochemical analysis of contractile
myofilaments. J Am Coll Cardiol 2002;39:963–9.
[13] Bruggink AH, van Oosterhout MF, de Jonge N, Cleutjens JP, van
Wichen DF, van Kuik J, et al. Type IV collagen degradation in the
myocardial basement membrane after unloading of the failing heart by
left ventricular assist device. Lab Invest 2007;87:1125–37.
[14] Kirwan RP, Fenerty CH, Crean J, Wordinger RJ, Clark AF, O'Brien
CJ. Influence of cyclical mechanical strain on extracellular matrix gene
expression in human lamina cribosa cells in vitro. Mol Vis 2005;11:
798–810.
[15] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the
comparative CT method. Nat Protoc 2008;3:1101–8.
[16] Pfister R, Acksteiner C, Baumgarth J, Burst V, Geissler HJ, Margulies
KB, et al. Loss of beta 1D-integrin function in humanischemic
cardiomyopathy. Basic Res Cardiol 2007;102:257–64.
[17] Hannigan GE, Coles JG, Dedhar S. Intergin-linked kinase at the heart
of cardiac contractility, repair and disease. Circ Res 2007;100:
1408–14.
[18] Casteldo C, Di Meglio F, Nurzynska D, Romano V, Miraglia R,
Bancone C, et al. CD117-positive cells in adult human heart are
localized in the subepicardium, and their activation is associated with
laminin-1 and alpha6 integrin expression. Stem Cells 2008;26:
1723–31.
[19] Maitra N, Flink IL, Bahl JJ, Morkin E. Expression of alpha and beta
integrins during terminal differentiation of cardiomyocytes. Cardio-
vasc Res 2000;47:645–7.
[20] Bruggink AH, Van Oosterhout MF, De Jonge N, Ivangh B, van Kuik J,
Voorbij R, et al. Reverse modeling of the myocardial extracellular
matrix after prolonged LVAD follows a biphasic pattern. J Heart Lung
Transplant 2006;25:1091–8.
[21] Hall JL, Birks EJ, Grindle S, Cullen ME, Barton PJ, Rider JE, et al.
Molecular signature recovery following combination left ventricular
298 H.F.J. Dullens et al. / Cardiovascular Pathology 21 (2012) 291–298assist device (LVAD) support and pharmacologic therapy. European
Heart J 2007;28:613–27.
[22] Schipper MEI, Lok SI, Dullens HFJ, Van Kuik J, Gmelig-Meyling
FHJ, Lahpor J, et al. Altered expression of mRNA and miRNA during
mechanical support of the failing heart. In: Intech Open Acces
Publishers, editor. Ventricular Assist Devices, 2011. In press.
[23] Thomas GJ, NyströmML, Marshall JF. Alphavbeta6 integrin in wound
healing and cancer of the oral cavity. J Oral Pathol Med 2006;35:1–10.[24] Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ. The
CD34-like protein PODXL and alpha6-integrin CD49f) identify early
progenitor MSCs with increased clonogenicity and migration to
infarcted heart in mice. Blood 2009;113:816–26.
[25] Birks EJ, Hall JL, Barton PJR, Grindle S, Latif N, Hardy JP, et al.
Gene profiling changes in cytoskeletal proteins during clinical
recovery after left ventricular-assist device support. Circulation 2005;
112:I57–64.
